Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperLetterpeer-review

  • Robert J. Motzer, Memorial Sloan-Kettering Cancer Center
  • ,
  • Paul Russo, Memorial Sloan-Kettering Cancer Center
  • ,
  • Naomi Haas, University of Pennsylvania
  • ,
  • Christian Doehn, University of Lübeck
  • ,
  • Frede Donskov
  • Marine Gross-Goupil, CHU de Bordeaux
  • ,
  • Sergei Varlamov, Altai Regional Cancer Center
  • ,
  • Evgeny Kopyltsov, State Institution of Healthcare Regional Clinical Oncology Dispensary
  • ,
  • Jae Lyun Lee, University of Ulsan
  • ,
  • Ho Yeong Lim, Sungkyunkwan University
  • ,
  • Bohuslav Melichar, Palacký University Olomouc
  • ,
  • Milada Zemanova, Charles University
  • ,
  • Brian Rini, Cleveland Clinic Foundation
  • ,
  • Toni K. Choueiri, Dana-Farber Cancer Institute
  • ,
  • Lori Wood, QEII Health Sciences Centre
  • ,
  • M. Neil Reaume, University of Ottawa
  • ,
  • Arnulf Stenzl, University of Tübingen
  • ,
  • Simon Chowdhury, St. Thomas' Hospital
  • ,
  • Ray McDermott, Tallaght University Hospital
  • ,
  • Agnieszka Michael, University of Surrey
  • ,
  • Miguel Izquierdo, Novartis
  • ,
  • Paola Aimone, Novartis
  • ,
  • Hong Zhang, Novartis
  • ,
  • Cora N. Sternberg, Cornell University

Adjuvant pazopanib does not extend overall survival compared to placebo in patients with locally advanced or metastatic renal cell carcinoma.

Original languageEnglish
JournalEuropean Urology
Volume79
Issue3
Pages (from-to)334-338
Number of pages5
ISSN0302-2838
DOIs
Publication statusPublished - Mar 2021

    Research areas

  • Pazopanib, Renal cell carcinoma, Tyrosine kinase inhibitor

See relations at Aarhus University Citationformats

ID: 213242731